ASH published a widely
cited practice guideline on the management of immune thrombocytopenia (ITP) in
1996. In the last 10 to 15 years since its
publication, there have been advances in the definition of ITP, as well as the
introduction of novel treatments (thrombopoietin receptor agonists, rituximab)
which are currently used in the management of patients with ITP. Given these developments, an evidence-based
update of these guidelines was undertaken and published last year (Neunert et
al. Blood 2011;117(16):4190).
Many areas in medicine are
based on practice with little supporting evidence. Clinicians should be aware
of the quality of the data supporting their management decisions and apply the
best available evidence in their clinical decision-making. This webinar reviewed the evidence supporting the 2011 guideline recommendations and highlighted
the important changes in the updated guideline for the diagnosis and treatment
of patients with ITP.
Update in Pediatric ITP
Cindy Neunert, MD, Georgia Health Sciences University, Augusta, GA
This presentation reviewed the diagnosis and management of
pediatric ITP, highlighting the changes made in the recent ASH ITP guideline as
well as issues unique to managing ITP in the pediatric population.
Update in Adult ITP
Mark Crowther, MD, Worcestershire Royal Hospital, Worcester, UK
This presentation reviewed the diagnosis and management of ITP
in adults, highlighting the changes made in the recent ASH ITP guideline and
discussing some of the controversial areas in the management of this disease.
Novel Agents in ITP Management
Lawrence Solberg, Jr, MD,
PhD, Mayo Clinic, Jacksonville, FL
This presentation discussed the use of the thrombopoietin receptor agonists and rituximab and their
role in ITP treatment based on the currently available evidence.
Wendy Lim, MD, MSc,
McMaster University, Hamilton, Canada
back to top